ZBH · Zimmer Biomet Holdings, Inc.

Zimmer Biomet reported robust Q1 results with revenue of $2.1 billion, up 9.3% from $1.9 billion in the prior year, primarily due to higher sales. The Paragon 28 acquisition contributed to volume growth, though its lower operating profit margin influenced overall profitability dynamics. Gross profit reached $1.5 billion, a 11.1% increase from $1.4 billion, supporting a steady gross margin of 72.4%. This resilience stemmed from operational efficiencies offsetting integration-related fair value adjustments from the acquisition.

Operating income advanced sharply to $373.2 million, up 27.7% from $292.3 million, as the benefit of higher sales volumes outweighed increased expenses. However, operating profit as a percentage of sales decreased due to investments in the sales force and higher bad debt charges, alongside the dilutive impact of Paragon 28's margin profile. These strategic investments position the company for sustained growth by enhancing commercial capabilities in key markets.

Net income surged 30.8% to $238.1 million from $182.0 million, with diluted EPS rising 34.1% to $1.22 from $0.91. The increase was driven by expanded net sales and a favorable adjustment related to probable U.S. tariffs paid in 2025, alongside ongoing savings from restructuring plans and non-recurrence of prior inventory charges. These factors underscore improved cost discipline and one-time tailwinds supporting bottom-line expansion.

Overall, the quarter reflects effective execution on growth initiatives like Paragon 28 integration, balancing topline momentum with targeted investments that may pressure near-term margins but enhance long-term competitiveness in orthopedics.